Jennifer Martin
ex MHRA Inspector
BSc (hon), Chemistry
Jennifer brings over 30 years of experience in the pharmaceutical industry, with expertise in EU and UK GxP regulations, guidance, and regulatory intelligence. Her career began with 12 years in GLP and GCP environments within the industry, followed by 15 years at the UK Medicines and Healthcare products Regulatory Agency (MHRA). There, she progressed from GCP Inspector to Lead Senior Inspector and ultimately Operations Manager, overseeing inspection teams and risk-based inspection programmes.
Whilst working at the MHRA Jennifer contributed to development of the MHRA GCP Guide, EU Clinical Trials Regulation (CTR), the UK Medicines & Medical Devices Act 2021, and guidance related to Brexit and COVID-19 regulatory flexibilities. She has collaborated with global authorities including the EMA and FDA, co-presenting at international fora and piloting the EMA/FDA joint inspection programme and the UK Innovative Licensing & Access Pathway. She also supported the development of remote GCP inspections during the pandemic to accelerate vaccine approvals.
After returning to industry as a Director of Quality, Jennifer focused on implementing pragmatic, proportionate GxP compliance and inspection readiness, for innovative products, trial designs, and technologies.
Jennifer is a seasoned auditor and inspector, with a strong track record in regulatory intelligence, quality impact assessments, and continuous improvement. Her approach is grounded in real-world experience, offering clients strategic insight and practical solutions.
Qualifications
BSc (hon), Chemistry
Jennifer Martin
ex MHRA Inspector